Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Erlotinib is a drug which targets non small cell lung cancer with a genetic change (mutation)
in the epidermal growth factor receptor (EGFR). This drug has been used in other cancer
research studies and information from those studies suggests that Erlotinib can control the
growth of these cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
David M. Jackman, MD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc.